2-(3-溴苯基)-2-氧代乙酸甲酯 | 81316-36-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(3-溴苯基)-2-氧代乙酸甲酯
• 英文名称: methyl 3-bromobenzoylformate
• 英文别名: Methyl 2-(3-bromophenyl)-2-oxoacetate
• CAS: 81316-36-1
• 化学式: C₉H₇BrO₃
• mdl: MFCD11973930
• 分子量: 243.057
• InChiKey: JHRVFNCYNNNVSI-UHFFFAOYSA-N

物化性质

• 熔点：
  53 °C
• 沸点：
  309.9±25.0 °C(Predicted)
• 密度：
  1.546±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918300090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(3-溴苯基)-2-氧代乙酸甲酯 在 二乙胺基三氟化硫 作用下， 反应 3.0h， 以76%的产率得到2-(3-溴苯基)-2,2-二氟乙酸甲酯
  参考文献：
  名称：

  Chiral β-diketonate ligands of ‘pseudo planar chiral’ topology: enantioselective synthesis and transition metal complexation

  摘要：

  A practical enantioselective synthesis of chiral beta-diketonate ligands 1a-1d, which are of 'pseudo planar-chiral' topology, is described. Additionally, the first chiral bis(diketonates) 2a-2c, ligands of C-2-symmetry that are isoelectronic with respect to related salen ligand systems, have been prepared. Protocols for the inetallation of ligands 1a-1d, 2b and 2c are reported. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2005.03.118
• 作为产物：
  描述：

  3-溴扁桃酸 在 manganese(IV) oxide 、 硫酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 2-(3-溴苯基)-2-氧代乙酸甲酯
  参考文献：
  名称：

  Chiral β-diketonate ligands of ‘pseudo planar chiral’ topology: enantioselective synthesis and transition metal complexation

  摘要：

  A practical enantioselective synthesis of chiral beta-diketonate ligands 1a-1d, which are of 'pseudo planar-chiral' topology, is described. Additionally, the first chiral bis(diketonates) 2a-2c, ligands of C-2-symmetry that are isoelectronic with respect to related salen ligand systems, have been prepared. Protocols for the inetallation of ligands 1a-1d, 2b and 2c are reported. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2005.03.118

文献信息

• Carbene‐Catalyzed Enantioselective Aromatic N‐Nucleophilic Addition of Heteroarenes to Ketones
  作者：Yonggui Liu、Guoyong Luo、Xing Yang、Shichun Jiang、Wei Xue、Yonggui Robin Chi、Zhichao Jin

  DOI：10.1002/anie.201912160

  日期：2020.1.2

  and optical purities. Our reaction involves the formation of an unprecedented aza-fulvene-type acylazolium intermediate. A broad range of N-heteroaromatic aldehydes and electron-deficient ketone substrates works effectively in this transformation. Several of the chiral N,O-acetal products afforded through this protocol exhibit excellent antibacterial activities against Ralstonia solanacearum (Rs) and

  杂芳基醛的芳族氮原子被卡宾催化剂活化以与酮亲电子试剂反应。以良好至优异的产率和光学纯度提供多功能的环状N，O-乙缩醛产物。我们的反应涉及空前的氮杂富烯型酰基唑鎓中间体的形成。各种各样的N-杂芳族醛和缺电子的酮底物可以有效地实现这种转化。通过该协议提供的几种手性N，O-乙缩醛产品表现出优异的抗青枯菌（Rsstonia solanacearum）的抗菌活性，在开发用于植物保护的新型农业化学品中具有重要的价值。
• VITAMIN D-LIKE COMPOUND
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1894911A1

  公开（公告）日：2008-03-05

  The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.

  本发明提供了一种由下列通式（I）表示的化合物： 或其药用的可接受盐，包含该化合物的药物组合物等。该化合物或其药用的可接受盐，包含该化合物的药物组合物等，用作治疗良性前列腺增生、癌症、骨质疏松症、银屑病、继发性甲状旁腺功能亢进、慢性肾小球肾炎、狼疮性肾炎和/或糖尿病性肾病等的药物等。
• [EN] BIARYL SUBSTITUTED PYRAZINONES AS SODIUM CHANNEL BLOCKERS<br/>[FR] PYRAZINONES SUBSTITUEES PAR BIARYLE UTILISEES COMME BLOQUANTS DES CANAUX SODIQUES
  申请人：MERCK & CO INC

  公开号：WO2005097136A1

  公开（公告）日：2005-10-20

  Biaryl substituted pyrazinone compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.

  公式I所代表的取代联苯基吡嗪酮化合物，或其药学上可接受的盐。药物组合物包括有效量的即时化合物，单独或与一个或多个其他治疗活性化合物结合，并含有药学上可接受的载体。治疗与或由钠通道活性相关的病症的方法，例如急性疼痛、慢性疼痛、内脏疼痛、炎症性疼痛、神经痛、尿失禁、瘙痒、过敏性皮炎、癫痫、肠易激综合征、抑郁症、焦虑症、多发性硬化症和躁郁症，包括给予有效量的目前化合物，单独或与一个或多个其他治疗活性化合物结合。一种给予局部麻醉的方法包括给予即时发明的化合物的有效量，单独或与一个或多个其他治疗活性化合物结合，并含有药学上可接受的载体。
• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES<br/>[FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2015042397A1

  公开（公告）日：2015-03-26

  Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

  本文描述了一种I式化合物，制备这种化合物的方法，含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与葡萄糖酰胺合成酶（GCS）相关的疾病或症状的方法。
• High-Potency Phenylquinoxalinone Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators
  作者：Jung-Ho Son、Jie S. Zhu、Puay-Wah Phuan、Onur Cil、Andrew P. Teuthorn、Colton K. Ku、Sujin Lee、Alan S. Verkman、Mark J. Kurth

  DOI：10.1021/acs.jmedchem.6b01759

  日期：2017.3.23

  We previously identified phenylquinoxalinone CFTRact-J027 (4) as a cystic fibrosis transmembrane conductance regulator (CFTR) activator with an EC50 of ∼200 nM and demonstrated its therapeutic efficacy in mouse models of constipation. Here, structure–activity studies were done on 36 synthesized phenylquinoxalinone analogs to identify compounds with improved potency and altered metabolic stability.

  我们之前鉴定出苯基喹喔啉酮CFTR act -J027（4）为EC 50为〜200 nM的囊性纤维化跨膜电导调节剂（CFTR）激活剂，并证明了其在便秘小鼠模型中的治疗效果。在这里，对36种合成的苯基喹喔啉酮类似物进行了结构活性研究，以鉴定具有增强的效力和改变的代谢稳定性的化合物。苯基喹喔啉酮核的合成通常通过1,2-苯二胺与取代的苯基氧乙酸酯的缩合来完成。结构活性研究除其他功能外，还确定了在3-芳基上适当定位的硝基部分的优先性质。与之相比，合成的类似物显示出更高的CFTR激活能力4的EC 50降至21 nM，具有更高的代谢稳定性。CFTR激活剂在便秘，干眼症，胆汁淤积性肝病和炎症性肺疾病中具有潜在的治疗适应症。